Avior Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $847K | Sell |
1,358
-41
| -3% | -$27.9K | 0.02% | 393 |
|
|
2026
Q1 | $1.08M | Sell |
1,399
-110
| -7% | -$84.2K | 0.03% | 335 |
|
|
2025
Q4 | $1.16M | Buy |
1,509
+46
| +3% | +$31.2K | 0.04% | 284 |
|
|
2025
Q3 | $823K | Buy |
1,463
+2
| +0.1% | +$1.13K | 0.03% | 338 |
|
|
2025
Q2 | $767K | Buy |
1,461
+581
| +66% | +$324K | 0.03% | 338 |
|
|
2025
Q1 | $558K | Sell |
880
-310
| -26% | -$213K | 0.02% | 374 |
|
|
2024
Q4 | $848K | Buy |
1,190
+268
| +29% | +$225K | 0.03% | 316 |
|
|
2024
Q3 | $969K | Buy |
922
+1
| +0.1% | +$1.11K | 0.04% | 296 |
|
|
2024
Q2 | $968K | Sell |
921
-65
| -7% | -$63K | 0.04% | 277 |
|
|
2024
Q1 | $949K | Sell |
986
-42
| -4% | -$39.9K | 0.04% | 299 |
|
|
2023
Q4 | $903K | Hold |
1,028
| – | – | 0.05% | 227 |
|
|
2023
Q3 | $846K | Buy |
1,028
+4
| +0.4% | +$3.14K | 0.06% | 220 |
|
|
2023
Q2 | $736K | Hold |
1,024
| – | – | 0.05% | 254 |
|
|
2023
Q1 | $841K | Hold |
1,024
| – | – | 0.06% | 225 |
|
|
2022
Q4 | $739K | Sell |
1,024
-217
| -17% | -$160K | 0.06% | 227 |
|
|
2022
Q3 | $854K | Hold |
1,241
| – | – | 0.07% | 188 |
|
|
2022
Q2 | $732K | Sell |
1,241
-375
| -23% | -$244K | 0.07% | 193 |
|
|
2022
Q1 | $1.13M | Sell |
1,616
-302
| -16% | -$191K | 0.1% | 146 |
|
|
2021
Q4 | $1.21M | Hold |
1,918
| – | – | 0.1% | 160 |
|
|
2021
Q3 | $1.16M | Hold |
1,918
| – | – | 0.1% | 158 |
|
|
2021
Q2 | $1.07M | Sell |
1,918
-249
| -11% | -$126K | 0.11% | 167 |
|
|
2021
Q1 | $1.02M | Sell |
2,167
-44
| -2% | -$21.4K | 0.11% | 171 |
|
|
2020
Q4 | $1.07M | Sell |
2,211
-102
| -4% | -$55.1K | 0.13% | 146 |
|
|
2020
Q3 | $1.29M | Buy |
2,313
+257
| +13% | +$156K | 0.18% | 119 |
|
|
2020
Q2 | $1.28M | Sell |
2,056
-93
| -4% | -$52.8K | 0.2% | 119 |
|
|
2020
Q1 | $1.05M | Buy |
2,149
+29
| +1% | +$12K | 0.21% | 119 |
|
|
2019
Q4 | $795K | Hold |
2,120
| – | – | 0.13% | 164 |
|
|
2019
Q3 | $587K | Buy |
2,120
+132
| +7% | +$39.1K | 0.1% | 188 |
|
|
2019
Q2 | $622K | Buy |
1,988
+72
| +4% | +$24K | 0.11% | 175 |
|
|
2019
Q1 | $786K | Hold |
1,916
| – | – | 0.17% | 129 |
|
|
2018
Q4 | $715K | Hold |
1,916
| – | – | 0.17% | 124 |
|
|
2018
Q3 | $774K | Hold |
1,916
| – | – | 0.17% | 124 |
|
|
2018
Q2 | $661K | Buy |
1,916
+202
| +12% | +$63.2K | 0.15% | 136 |
|
|
2018
Q1 | $590K | Buy |
1,714
+119
| +7% | +$41.4K | 0.14% | 149 |
|
|
2017
Q4 | $600K | Buy |
1,595
+1,570
| +6,280% | +$636K | 0.13% | 147 |
|
|
2017
Q3 | $11K | Hold |
25
| – | – | ﹤0.01% | 328 |
|
|
2017
Q2 | $12K | Hold |
25
| – | – | ﹤0.01% | 297 |
|
|
2017
Q1 | $10K | Buy |
+25
| New | +$9.27K | ﹤0.01% | 351 |
|
Other funds holding REGN
Avior Wealth Management's REGN Position: Q2 2026 in Review
Avior Wealth Management reduced its Regeneron Pharmaceuticals (REGN) stake by 2.9% in Q2 2026, selling an estimated $27.9K and leaving 1,358 shares worth $847K. The position accounts for 0.02% of the portfolio, ranked #393.
Avior Wealth Management first reported a position in REGN in Q1 2017 and has held it in 38 quarters since. The position peaked at $1.29M in Q3 2020. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Avior Wealth Management held 1,358 shares of Regeneron Pharmaceuticals worth $847K as of Q2 2026.
- Avior Wealth Management sold 41 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $27.9K.
- Regeneron Pharmaceuticals made up 0.02% of Avior Wealth Management's portfolio in Q2 2026, its #393 holding.
- Avior Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2017 and has held it in 38 quarters since.
- Avior Wealth Management's Regeneron Pharmaceuticals position peaked at $1.29M in Q3 2020.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Avior Wealth Management's 13F filing for Q2 2026, filed 7 Jul 2026.